Motexafin gadolinium: A novel redox active drug for cancer therapy

Seminars in Cancer Biology

Volumn 16, Issue 6, 2006, Pages 466-476

  Magda, Darren ^a   Miller, Richard A ^a  

^a PHARMACYCLICS INC   (United States)

Author keywords

Brain metastasis; Motexafin gadolinium; Reactive oxygen species; Thioredoxin reductase; Zinc

Indexed keywords

BORTEZOMIB; CARBOPLATIN; CELECOXIB; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GADOLINIUM TEXAPHYRIN; PEMETREXED; REACTIVE OXYGEN METABOLITE; RITUXIMAB;

ANTINEOPLASTIC ACTIVITY; BRAIN METASTASIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER THERAPY; CELL METABOLISM; CLINICAL TRIAL; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG RETENTION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; IONIZING RADIATION; KIDNEY CARCINOMA; LEUKEMIA; LIVER TOXICITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; NONHUMAN; OXIDATION REDUCTION REACTION; REVIEW; TOXICITY TESTING;

ANTINEOPLASTIC AGENTS; HUMANS; METALLOPORPHYRINS; NEOPLASMS; OXIDATION-REDUCTION;

EID: 33751181914     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2006.09.002     Document Type: Review

References (66)

1. Sessler J.L., and Miller R.A. Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol 59 April (7) (2000) 733-739
2. Carde P., Timmerman R., Mehta M.P., Koprowski C.D., Ford J., Tishler R., et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 19 April (7) (2001) 2074-2083
3. Mehta M.P., Shapiro W.R., Glantz M.J., Patchell R.A., Weitzner M.A., Meyers C.A., et al. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 20 August (16) (2002) 3445-3453
4. Rosenthal D.I., Nurenberg P., Becerra C.R., Frenkel E.P., Carbone D.P., Lum B.L., et al. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 5 April (4) (1999) 739-745
5. Rockson S.G., Kramer P., Razavi M., Szuba A., Filardo S., Fitzgerald P., et al. Photoangioplasty for human peripheral atherosclerosis: results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin). Circulation 102 November (19) (2000) 2322-2324
6. Mehta M.P., Rodrigus P., Terhaard C., Rao A., Suh J., Roa W., et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole brain radiation therapy in brain metastases. J Clin Oncol 21 (2003) 2529-2536
7. Khuntia D., and Mehta M. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors. Expert Rev Anticancer Ther 4 6 (2004) 981-989
8. Sessler J.L., Murai T., Lynch V., and Cyr M. An "expanded porphyrin": the synthesis and structure of a new aromatic pentadentate ligand. J Am Chem Soc 110 (1988) 5586-5588
9. Young S.W., Sidhu M.K., Qing F., Muller H.H., Neuder M., Zanassi G., et al. Preclinical evaluation of gadolinium(III) texaphyrin complex: a new paramagnetic contrast agent for magnetic resonance imaging. Invest Radiol 29 March (3) (1994) 330-338
10. Sessler J.L., Tvermoes N.A., Guldi D.M., Mody T.D., and Allen W.E. One-electron reduction and oxidation studies of the radiation sensitizer gadolinium(III) texaphyrin (PCI-0120) and other water soluble metallotexaphyrins. J Phys Chem A 103 (1999) 787-794
11. 2+, Xcytrin). J Phys Chem B 105 (2001) 1452-1457
12. Magda D., Lepp C., Gerasimchuk N., Lee I., Sessler J.L., Lin A., et al. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys 51 November (4) (2001) 1025-1036
13. Buettner G.R. The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch Biochem Biophys 300 February (2) (1993) 535-543
14. Magda D., Gerasimchuk N., Lecane P., Miller R.A., Biaglow J.E., and Sessler J.L. Motexafin gadolinium reacts with ascorbate to produce reactive oxygen species. Chem Commun (2002) 2730-2731
15. Hornig D. Distribution of ascorbic acid, metabolites and analogues in man and animals. Ann NY Acad Sci 258 September (1975) 103-118
16. Langemann H., Torhorst J., Kabiersch A., Krenger W., and Honegger C.G. Quantitative determination of water- and lipid-soluble antioxidants in neoplastic and non-neoplastic human breast tissue. Int J Cancer 43 June (6) (1989) 1169-1173
17. Eberhardt M. Reactive oxygen metabolites (2001), CRC Press, Boca Raton, FL
18. Biaglow J.E., Varnes M.E., Clark E.P., and Epp E.R. The role of thiols in cellular response to radiation and drugs. Radiat Res 95 September (3) (1983) 437-455
19. ®): a redox active agent that reacts with electron-rich biological substrates. In: Sessler JL., Doctrow SR., McMurry TJ., Lippard SJ., editors. Medicinal Inorganic Chemistry (ACS Symposium Series 903), Washington, D.C.: American Chemical Society; 2005, p. 110-36.
20. Hashemy S.I., Ungerstedt J.S., Avval F.Z., and Holmgren A. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J Biol Chem 281 16 (2006) 10691-10697
21. Mani C., Upadhyay S., Lacy S., Boswell G.W., and Miles D.R. Reductase-mediated metabolism of motexafin gadolinium (xcytrin) in rat and human liver subcellular fractions and purified enzyme preparations. J Pharm Sci 94 3 (2005) 559-570
22. Rosenkranz A.R., Schmaldienst S., Stuhlmeier K.M., Chen W., Knapp W., and Zlabinger G.J. A microplate assay for the detection of oxidative products using 2′,7′-dichlorofluorescin-diacetate. J Immunol Methods 156 November (1) (1992) 39-45
23. Rockwell S., Donnelly E., Liu Y., and Tang L. Preliminary studies of the effects of gadolinium texaphyrin on the growth and radiosensitivity of EMT6 cells in vitro. Int J Radiat Oncol Biol Phys 54 October (2) (2002) 536-541
24. Evens A.M., Lecane P., Magda D., Prachand S., Singhal S., Nelson J., et al. Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. Blood 105 February (3) (2005) 1265-1273
25. Magda D., Lecane P., Miller R.A., Lepp C., Miles D., Mesfin M., et al. Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines. Cancer Res 65 9 (2005) 3837-3845
26. Lipshutz R.J., Fodor S.P., Gingeras T.R., and Lockhart D.J. High density synthetic oligonucleotide arrays. Nat Genet 21 January (Suppl. 1) (1999) 20-24
27. Coyle P., Philcox J.C., Carey L.C., and Rofe A.M. Metallothionein: the multipurpose protein. Cell Mol Life Sci 59 April (4) (2002) 627-647
28. Langmade S.J., Ravindra R., Daniels P.J., and Andrews G.K. The transcription factor MTF-1 mediates metal regulation of the mouse ZnT1 gene. J Biol Chem 275 November (44) (2000) 34803-34809
29. Lichtlen P., Wang Y., Belser T., Georgiev O., Certa U., Sack R., et al. Target gene search for the metal-responsive transcription factor MTF-1. Nucleic Acids Res 29 April (7) (2001) 1514-1523
30. Biaglow J.E., Donahue J., Tuttle S., Held K., Chrestensen C., and Mieyal J. A method for measuring disulfide reduction by cultured mammalian cells: relative contributions of glutathione-dependent and glutathione-independent mechanisms. Anal Biochem 281 May (1) (2000) 77-86
31. Lecane P., Karaman M.W., Sirisawad M., Naumovski L., Miller R.A., Hacia J.G., et al. Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res 65 24 (2005) 1-13
32. Freeman R.S., Hasbani D.M., Lipscomb E.A., Straub J.A., and Xie L. SM-20, EGL-9, and the EGLN family of hypoxia-inducible factor prolyl hydroxylases. Mol Cells 16 August (1) (2003) 1-12
33. Dinkova-Kostova A.T., Holtzclaw W.D., Cole R.N., Itoh K., Wakabayashi N., Katoh Y., et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci USA 99 September (18) (2002) 11908-11913
34. Holmgren A. Thioredoxin. Annu Rev Biochem 54 (1985) 237-271
35. Lenartowicz E., and Wudarczyk J. Enzymatic reduction of 5,5′-dithiobis-(2-nitrobenzoic acid) by lysate of rat liver mitochondria. Int J Biochem Cell Biol 27 (1995) 831-837
36. Chen J., Ramos J., Sirisawad M., Miller R., and Naumovski L. Motexafin gadolinium induces mitochondrially mediated caspase-dependent apoptosis. Apoptosis 10 5 (2005)
37. Zhao R., Gish K., Murphy M., Yin Y., Notterman D., Hoffman W.H., et al. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 14 April (8) (2000) 981-993
38. Perez O.D., Nolan G.P., Magda D., Miller R.A., Herzenberg L.A., and Herzenberg L.A. Motexafin gadolinium (Gd-Tex) selectively induces apoptosis in HIV-1 infected CD4+ T helper cells. Proc Natl Acad Sci USA 99 February (4) (2002) 2270-2274
39. Miller R.A., Woodburn K.W., Fan Q., Lee I., Miles D., Duran G., et al. Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin. Clin Cancer Res 7 October (10) (2001) 3215-3221
40. Voehringer D.W., Hirschberg D.L., Xiao J., Lu Q., Roederer M., Lock C.B., et al. Gene microarray identification of redox and mitochondrial elements that control resistance or sensitivity to apoptosis. Proc Natl Acad Sci USA 97 March (6) (2000) 2680-2685
41. Biaglow J.E., Ayene I.S., Koch C.J., Donahue J., Stamato T.D., and Tuttle S.W. G6PD deficient cells and the bioreduction of disulfides: effects of DHEA, GSH depletion and phenylarsine oxide. Biochem Biophys Res Commun 273 July (3) (2000) 846-852
42. Naumovski L., Chen J., Ramos J., Lecane P., Magda D., Evens A., et al. Inhibition of growth and induction of apoptosis by motexafin gadolinium (Xcytrin®) alone and in combination with other therapeutic agents in lymphoma and myeloma tumor cell lines. Blood 102 (2003) 213b
43. Miller R., Fan Q., Lee I., and Magda D. Motexafin gadolinium (Gd) increases tumor response to chemotherapy in Lewis lung cancer (LLC) animal model. ASCO Proceedings, 21 (2002) 117a
44. Chen J., Ramos J., Sirisawad M., Miller R.A., and Naumovski L. Motexafin gadolinium enhances rituximab-induced cytotoxicityagainst b-cell lymphoma cell lines. Blood 104 (2004) 3406
45. Naumovski L., Bone N.D., Sirisawad M., Miller R.A., Jelinek D.F., Tschumper R.C., et al. Motexafin gadolium, a redox mediator, induces apoptosis in chronic lymhocytic leukemia B-cells and is additive or synergistic with fludarabine. AACR 46 (2005) 1209
46. Naumovski L., Ramos J., Sirisawad M., Chen J., Fu L., and Miller R. Potentiation of motexafin gadolinium cytotoxicity by celecoxib but not other cyclooxygenase-2 inhibitors. AACR 46 (2005) 1165
47. Young S.W., Qing F., Harriman A., Sessler J.L., Dow W.C., Mody T.D., et al. Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci USA 93 June (13) (1996) 6610-6615 [published correction appears in Proc Natl Acad Sci USA. 1999; 96:2569]
48. Boswell G.W., Miles D.R., Thiemann P.A., and Mesfin M. Population pharmacokinetics and bioavailability of motexafin gadolinium (Xcytrin) in CD1 mice following intravenous and intraperitoneal injection. Invest New Drugs 24 July (4) (2006) 281-289
49. Miles D.R., Mesfin M., Mody T.D., Stiles M., Lee J., Fiene J., et al. Validation and use of three complementary analytical methods (LC-FLS, LC-MS/MS and ICP-MS) to evaluate the pharmacokinetics, biodistribution and stability of motexafin gadolinium in plasma and tissues. Anal Bioanal Chem 385 May (2) (2006) 345-356
50. Miller R.A., Woodburn K., Fan Q., Renschler M.F., Sessler J.L., and Koutcher J.A. In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int J Radiat Oncol Biol Phys 45 November (4) (1999) 981-989
51. Xu S., Zakian K., Thaler H., Matei C., Alfieri A., Chen Y., et al. Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity. Int J Radiat Oncol Biol Phys 49 April (5) (2001) 1381-1390
52. Bohmer R.M., and Morstyn G. Uptakae of hematoporphyrin derivative by normal and malignant cells: Effect of serum, ph, temperature, and cell size. Cancer Res 45 (1985) 5328-5334
53. Byrne A.T., Magda D., Nguyen H., Miles D., Boswell G., and Miller R.A. Selective tumor localization wwith motexafin gadolinium (MGd) and motexafin lutetium (MLu) occurs by active transport. (2003), AACR; American Association for Cancer Research (AACR), Toronto, Ontario, Canada p. 393
54. Woodburn K.W. Intracellular localization of the radiation enhancer motexafin gadolinium using interferometric Fourier fluorescence microscopy. J Pharmacol Exp Ther 297 June (3) (2001) 888-894
55. Woodburn K.W., Fan Q., Miles D.R., Kessel D., Luo Y., and Young S.W. Localization and efficacy analysis of the phototherapeutic lutetium texaphyrin (PCI-0123) in the murine EMT6 sarcoma model. Photochem Photobiol 65 March (3) (1997) 410-415
56. Lee I., Magda D., Lepp C., Miller R., and Biaglow J. The inhibitory effect of motexafin gadolinium (MGd) on potentially lethal damage repair (PLDR) after exposure to continuous or intermittent doses of ionizing radiation in vitro. Proc Am Assoc Cancer Res 43 (2002) 647
57. Donnelly E.T., Liu Y., Fatunmbi Y.O., Lee I., Magda D., and Rockwell S. Effects of texaphyrins on the oxygenation of EMT6 mouse mammary tumors. Int J Radiat Oncol Biol Phys 58 5 (2004) 1570-1576
58. Miles D.R., Smith J.A., Phan S.-C., Hutcheson S.J., Renschler M.F., Ford J.M., et al. Population pharmacokinetics of motexafin gadolinium in adults with brain metastases or glioblastoma multiforme. J Clin Pharmacol 45 3 (2005) 299-312
59. Mehta M.P., Rodrigus P., Terhaard C., Roo A., Suh J., Roa W., et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21 (2003) 2529-2536
60. Mehta M., Gervais R., Chabot P., Shapiro W.R., Patchell R.A., Glantz M.J., et al. Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: results of a Phase 3 trial. J Clinl Oncol 24 188 (2006) 367s
61. Csiki I., Yanagisawa K., Haruki N., Nadaf S., Morrow J.D., Johnson D.H., et al. Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer. Cancer Res 66 January (1) (2006) 143-150
62. Kakolyris S., Giatromanolaki A., Koukourakis M., Powis G., Souglakos J., Sivridis E., et al. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 7 October (10) (2001) 3087-3091
63. Arner E.S.J., and Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267 (2000) 6102-6109
64. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 October (10) (2003) 721-732
65. Matoba S., Kang J.G., Patino W.D., Wragg A., Boehm M., Gavrilova O., et al. p53 Regulates mitochondrial respiration. Science May (2006)
66. Gambhir S.S. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2 September (9) (2002) 683-693